Intersect Capital’s Novartis NVS Stock Holding History

Intersect Capital’s Portfolio NVS Stock Details NVS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q2	$398K	Buy	4,710 +450	+11%	+$39.5K	0.12%	185
2022 Q1	$374K	Buy	4,260 +1,067	+33%	+$92.4K	0.07%	260
2021 Q4	$279K	Buy	3,193 +52	+2%	+$4.32K	0.05%	327
2021 Q3	$257K	Sell	3,141 -455	-13%	-$40.9K	0.04%	311
2021 Q2	$328K	Buy	3,596 +708	+25%	+$63K	0.06%	244
2021 Q1	$247K	Buy	2,888 +115	+4%	+$10.3K	0.05%	278
2020 Q4	$262K	Buy	2,773 +365	+15%	+$31.9K	0.06%	234
2020 Q3	$209K	Buy	+2,408	New	+$209K	0.06%	219
2015 Q2	–	Sell	-812	Closed	-$74K	–	279
2015 Q1	$74K	Hold	812	–	–	0.06%	147
2014 Q4	$67K	Buy	+812	New	+$67.3K	0.06%	160

Other funds holding NVS

Dodge & Cox San Francisco, California $191B AUM 17.5% 1-Year Est. Return

Primecap Management Pasadena, California $169B AUM 114.72% 1-Year Est. Return

Loomis, Sayles & Company Boston, Massachusetts $79.8B AUM 16.05% 1-Year Est. Return

Fisher Asset Management Camas, Washington $336B AUM 34.66% 1-Year Est. Return

Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

Boston Partners Boston, Massachusetts $113B AUM 38.87% 1-Year Est. Return

Intersect Capital's NVS Position: Q2 2022 in Review

Intersect Capital increased its Novartis (NVS) stake by 11% in Q2 2022, buying an estimated $39.5K and bringing the position to 4,710 shares worth $398K. The position accounts for 0.12% of the portfolio, ranked #185.

Intersect Capital first reported a position in NVS in Q4 2014 and has held it in 10 quarters since. 1,141 funds tracked by Wall St. Rank hold NVS as of Q2 2022.

Intersect Capital held 4,710 shares of Novartis worth $398K as of Q2 2022.
Intersect Capital bought 450 Novartis shares in Q2 2022, an estimated $39.5K.
Novartis made up 0.12% of Intersect Capital's portfolio in Q2 2022, its #185 holding.
Intersect Capital first reported a position in Novartis in Q4 2014 and has held it in 10 quarters since.
1,141 funds tracked by Wall St. Rank held Novartis as of Q2 2022.

Based on Intersect Capital's 13F filing for Q2 2022, filed 2 Sep 2022.